---
title: Detect Parkinson disease related lesions
nct_id: NCT07685873
status: RECRUITING
sponsor: Tianjin Medical University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07685873"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07685873"
last_fetched: "2026-07-06T14:00:30.968Z"
source: "Parkinson's Pathways (curated)"
---
# Detect Parkinson disease related lesions

**Goal (in five words):** Detect Parkinson disease related lesions

**Official Title:** Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

**Trial ID:** [NCT07685873](https://clinicaltrials.gov/study/NCT07685873)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Tianjin Medical University
- **Target Enrollment:** 200 participants
- **Start Date:** 2026-06-25
- **Completion Date:** 2029-07-01
- **Conditions:** Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
- **Interventions:** Diagnostic Test: 18F-FPyCO/SMBT-1
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to see whether a new PET/CT imaging agent, called 18F-FPyCO/SMBT-1, can help detect primary and metastatic lesions in conditions linked to the enzyme monoamine oxidase B, including Parkinson disease and related disorders. Participants get a PET/CT scan with the agent; researchers will measure how much tracer shows up in lesions using the maximum standard uptake value, and then calculate how well the scan finds true disease and avoids false alarms. The study is looking for adults 18 to 90 years old with suspected, newly diagnosed, or previously treated Parkinson disease or related conditions who are already scheduled for a PET/CT scan and can give informed consent; pregnant people and those with non-malignant lesions are excluded.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.

**Visits** _(From the protocol)_: Each subject will have a single study injection and imaging visit; timing is described only as "within the specificed time".
  > "Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/CT or MRI imaging within the specificed time."

**Procedures** _(From the protocol)_:
- Intravenous infusion (Minimally invasive)
  > "Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/CT or MRI imaging within the specificed time."
- Injection (Minimally invasive)
  > "Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/CT or MRI imaging within the specificed time."
- PET scan (Minimally invasive)
  > "To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients."
- MRI scan (Non-invasive)
  > "Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/CT or MRI imaging within the specificed time."

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
```

## Locations (2)

- The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China _(31.8639, 117.2808)_
  - Qiang Xie, PhD, (CONTACT), +8613721108043, ahxq1980@163.com
- Tianjin Medical University General Hospital, Tianjin, Tian, China _(39.1422, 117.1767)_
  - Ying Wang, MD, (CONTACT), +8618702292537, macrossplusvoices@163.com

## Central Contacts

- Ying Wang, MD, (CONTACT), +8618702292537, macrossplusvoices@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07685873*  
*HTML version: https://parkinsonspathways.com/trial/NCT07685873*  
*Source data: https://clinicaltrials.gov/study/NCT07685873*